Indivior
Develops monthly injectable and sublingual medicines for opioid use disorder.
$34.87
After-hours close0.00 (0.00%)
At close$34.87(−1.22%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 102.12%Insiders 1.24%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 124.77M · Float 112.13M · 89.9% free float
Institutions13F, as of Jun 30, 2026
347 holders · 127.42M shares · 91 new positions · 207 increased · 107 reduced · 43 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 18.71M | 15.00% | +167.2K | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 7.57M | 6.07% | −319.5K | Aug 13, 2026 |
| Oaktree Capital Management LP | 6.13M | 4.91% | −856.9K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 5.50M | 4.40% | −91.1K | Aug 13, 2026 |
| State Street Corp | 4.99M | 4.00% | +88.1K | Aug 7, 2026 |
| Fuller & Thaler Asset Management, Inc. | 4.62M | 3.70% | +86.2K | Aug 12, 2026 |
| Two Seas Capital LP | 3.48M | 2.79% | −1.27M | Aug 12, 2026 |
| Morgan Stanley | 3.40M | 2.72% | −110.1K | Aug 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 14.30% | 17.81M | 13G | Jan 8, 2026 ↗ |
| Vanguard Portfolio Management | 6.55% | 7.99M | 13G | Apr 28, 2026 ↗ |
| The Goldman Sachs Group, Inc. | 6.50% | 8.09M | 13G | Feb 6, 2025 ↗ |
| Deerfield Partners, L.P.incl. James E. Flynn, Deerfield Mgmt, L.P. +1 more | 5.80% | 7.36M | 13G | Nov 15, 2024 ↗ |
| Oaktree Capital Holdings, LLCincl. Oaktree London Liquid Value Opportunities Fund (VOF), L.P., Oaktree Value Opportunities Fund, L.P. +4 more | 5.69% | 7.11M | 13D | Dec 30, 2025 ↗ |
| Vanguard Capital Management | 5.35% | 6.52M | 13G | Apr 27, 2026 ↗ |
| Fuller & Thaler Asset Management, Inc. | 5.10% | 6.37M | 13G | Feb 17, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Joseph Ciaffoni | director, officer: Chief Executive Officer | 790.3K | 0.63% | Jun 23, 2026 |
| Ryan Preblick | officer: Chief Financial Officer | 284.8K | 0.23% | Jun 10, 2026 |
| Christian Heidbreder | officer: Chief Scientific Officer | 209.3K | 0.17% | Jul 13, 2026 |
| Jeffrey W. Burris | officer: Chief Legal Officer | 71.5K | 0.06% | Mar 5, 2026 |
| Patrick A. Barry | officer: Chief Commercial Officer | 31.4K | 0.03% | Feb 12, 2026 |
| David E. Wheadon | director | 30.8K | 0.02% | May 14, 2026 |
| Woodrow D. Anderson | officer: Chief Accounting Officer | 27.6K | 0.02% | Aug 27, 2026 |
| Daniel A. Ninivaggi | director | 27.2K | 0.02% | May 14, 2026 |
| Mark Stejbach | director | 27.1K | 0.02% | May 14, 2026 |
| Keith Humphreys | director | 16.0K | 0.01% | May 14, 2026 |
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 27, 2026 | Woodrow D. Andersonofficer: Chief Accounting Officer | Purchase | 1,500 | $35.69 | 27,638 |
| Aug 5, 2026 | Woodrow D. Andersonofficer: Chief Accounting Officer | Purchase | 1,500 | $36.28 | 26,138 |
| Jul 10, 2026 | Christian Heidbrederofficer: Chief Scientific Officer | Sale | 18,586 | $41.14 | 209,337 |
| Jun 11, 2026 | Christian Heidbrederofficer: Chief Scientific Officer | Sale | 18,586 | $38.06 | 227,923 |
| Jun 8, 2026 | Ryan Preblickofficer: Chief Financial Officer | Sale | 36,000 | $37.70 | 284,751 |
| Mar 13, 2026 | Barbara Ryandirector | Purchase | 8 | $31.09 | 5,724 |
| Mar 9, 2026 | Barbara Ryandirector | Purchase | 31 | $32.56 | 5,716 |
| Mar 6, 2026 | Stuart A. Kingsleydirector | Purchase | 940 | $31.87 | 5,582 |
| Jan 5, 2026 | David E. Wheadondirector | Purchase | 1,771 | $35.39 | 14,395 |
| Jan 5, 2026 | Mark Stejbachdirector | Purchase | 775 | $35.39 | 16,847 |
CongressHouse and Senate disclosures
Not reported.